Compare Flex Ltd (FLEX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flex Ltd vs Organon & Co. Common Stock — how do they compare? Flex Ltd trades at $98.72 (market cap $40.97B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Flex Ltd is far larger — about 11.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Flex Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| FLEX | OGN | |
|---|---|---|
Market Cap | $40.97B | $3.62B |
Volume | 5,533,554 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $162.07 | $13.81 |
52-Week Low | $54.51 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $44.06B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLEX trades at $110.88, down 5.42% over the past day, amid a broader market pullback. The stock maintains a bullish technical trend with strong analyst support, including a consensus price target of $147.50. Recent acquisitions like EPC Power and the planned spin-off of Axiom highlight strategic moves to capitalize on AI data center and power infrastructure growth. Fundamentals show solid profitability with a net income margin of 3.32% and revenue growth to $29.3B projected for 2026.
The outlook for FLEX is positive, driven by expansion in AI infrastructure and consistent earnings beats. Investment opportunities include potential upside from the Axiom spin-off and continued demand in cloud and power sectors. Key risks involve integration challenges from acquisitions, competitive pressures, and market volatility affecting valuation multiples.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flex Ltd
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
